A Randomized, Open Label, 2-Period, Cross-over Study to Evaluate the Bioequivalence of the Oversea Manufactured Sample and Domestic Manufactured Sample in Single Intravenous Dose of MB-102 (Relmapirazin) (Part I), and an Efficacy Study to Assess the Performance of the MediBeacon Transdermal GFR Measurement System and Domestic Manufactured Sample of MB-102 (Relmapirazin) for Evaluation of Kidney Function in Chinese Normal and Renal Compromised Subjects (Part II)
Latest Information Update: 23 Oct 2024
At a glance
- Drugs Relmapirazin (Primary)
- Indications Acute kidney injury; Kidney disorders
- Focus Registrational; Therapeutic Use
- Sponsors Hangzhou Zhongmei Huadong Pharmaceutical
Most Recent Events
- 28 Dec 2023 Status changed from recruiting to completed.
- 18 Jul 2023 New trial record